News

Video

Evolving Insights into Castration Resistance: Novel Biomarkers Predicting Disease Progression

Author(s):

Rana R. McKay, MDTanya B. Dorff, MD

Dr. Tanya Dorff and Dr. Rana McKay discuss the mechanisms driving castration resistance and how emerging epigenetic biomarkers may transform prognosis.

Related Videos
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Anthony V. D'Amico, MD, PhD
Video 6 - "Reflex Testing for Patients with Suspected Lung Cancer"
Video 5 "Biomarker Testing in Early-Stage NSCLC"
Stephen J. Freedland, MD
Timothy Yap, MBBS, PhD, FRCP
Timothy Yap, MBBS, PhD, FRCP
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Related Content
W. Robert Lee, MD, MEd, MS
June 12th 2024

Hypofractionation is Noninferior to Conventional Fractionation Radiotherapy in Low-Risk Prostate Cancer

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Daniel P. Petrylak, MD, of Yale School of Medicine
June 10th 2024

ARV-766 Demonstrates Clinical Activity in AR LBD–Mutated Metastatic CRPC

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Ronald C. Chen, MD, MPH, FASCO, FASTRO
June 6th 2024

Intensification With Apalutamide/ADT Improves PSA PFS in Biochemically Recurrent Prostate Cancer

Stephen J. Freedland, MD
June 5th 2024

Enzalutamide Treatment Suspension Has No Significant Impact on QOL in nmHSPC